Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients

NCT03792763 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
DRUG: Placebo 1.7 ml Subcutaneous Solution

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborators

[object Object]
[object Object]